Journal

Role of Platelets in Chronic Kidney Disease

Read time: 1 mins

Published:16th Jun 2021

Author: Jain N, Corken A, Kumar A, Davis C, Ware J, Arthur J.

Source: Journal of the American Society of Nephrology

Availability: Pay for access, or by subscription

Ref.:J Am Soc Nephrol. 2021 Jun 17:ASN.2020121806.

DOI:10.1681/ASN.2020121806

Role of Platelets in Chronic Kidney Disease

Platelet-dependent mechanisms for excessive clotting and bleeding in CKD remain undefined. Moreover, platelets’ contribution to inflammation, and specifically to CKD, are equally elusive. To date, descriptions of changes in the functional properties of circulating platelets during CKD have provided confusing interpretations. Experimental approaches that can advance our understanding of platelet dysfunction in CKD are needed, and studies that provide mechanistic insights into the dynamic relationships between thrombosis, bleeding, and inflammation associated with CKD will be essential to improve clinical management and outcomes for this vulnerable population. This article summarizes existing literature characterizing platelets in CKD and identifies areas that need further investigation.

Read abstract on library site Access full article

Hyperkalaemia

Containing relevant Learning Zones, guidelines, trials and news.

A digital image of two human kidneys, stylised in blue and red

Chronic Kidney Disease

Containing relevant Learning Zones, guidelines, trials and news.

Digital close up of human kidney glomerulus and the Bowman Capsule

Glomerulonephritis

Containing relevant Learning Zones, guidelines, trials and news.

Featured Learning Zones

patient receiving dialysis, hospital image

Learning Zone

Chronic Kidney Disease Learning Zone

Chronic Kidney Disease (CKD) is a disease that can often lead to a need for haemodialysis and kidney transplantation. New CKD treatments are emerging which focus on delaying CKD disease progression and the need for transplantation.

You may be interested in...

Guideline

Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) for the diagnosis of Cushing's syndrome: Genetics of Cushing's syndrome

Recent advancements in high-throughput sequencing have significantly enhanced our understanding of the genetics behind Cushing’s syndrome. Experts from the French Society of Endocrinology and French Society of Endocrinology and Pediatric Endocrinology reviewed genetic predispositions, resulting in a consensus statement on screening for Cushing disease and adrenal Cushing’s syndrome. Discover their key findings and recommendations.

Guideline

Consensus on diagnosis and management of Cushing's disease: a guideline update

The Pituitary Society’s Consensus Workshop brought together over 50 experts to refine the clinical approach to Cushing’s disease. This comprehensive review and collaborative discussion resulted in updated recommendations for diagnosis, treatment, and management, highlighting key areas for future research. Discover the latest consensus on optimizing patient outcomes in Cushing’s disease.

Guideline

Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024

Background and purpose: Two novel enzyme replacement therapies (ERTs), studied in phase 3 trials in late-onset Pompe patients, reached marketing authorization by the European Medicines Agency in 2022 and 2023. The European Pompe Consortium (EPOC) updates and extends the scope of the 2017 recommendations for starting, switching and stopping ERT.